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CASE REPORT
Abstract: A series of cases are reported in which patients on aripiprazole have developed
akathisia, although the literature states that the rate is negligible.
Keywords: aripiprazole, akathisia
Introduction
Aripiprazole has been shown to have a favorable extrapyramidal symptom (EPS)
risk profile in both short-term as well as long-term randomized double-blind clinical
trials (Harrison and Perry 2004). The incidence of EPS and related adverse events is
low when compared with both conventional and atypical antipsychotic agents
(Lieberman 2002). In clinical trials with acutely psychotic patients, aripiprazole has
similar efficacy to haloperidol and risperidone in the reduction of psychotic symptoms,
although a considerably superior profile in the reduction of side-effects, namely extra-
pyramidal side-effects, akathisia, and dyskinetic movements (Potkin et al 2003).
Prevalence of akathisia in short-term trials (up to 4–6 weeks) is 12% vs 5% in placebo
for schizophrenia and 15% vs 4% (placebo) for bipolar mania (Marder et al 2003).
Development of akathisia has also been reported in bipolar disorder (Cohen et al
2005).
Aripiprazole is a novel antipsychotic whose mechanism is unique in that it has a
partial agonist activity at dopamine D2 receptors (Burris et al 2002). It is also believed
to have D2 antagonist activity under hyperdopaminergic conditions and D2 agonist
activity under hypodopaminergic conditions. In addition, it is a partial agonist at
serotonin 5HT1A receptors and an antagonist at 5HT2A receptors (Jordan et al 2002).
Initial studies showed no significant difference for akathisia for patients receiving
placebo vs aripiprazole and no dose-response relationship was noted (Marder et al
2003). It was noted to be equally common in people allocated to aripiprazole,
olanzapine, and risperidone (El Sayeh and Morganti 2005).
We report a case series about akathisia noted in patients treated with aripiprazole
who were concurrently receiving selective serotonin receptor inhibitors (SSRI).
Case reports
During the course of their psychiatric care in the outpatient clinic, four individuals
developed akathisia when started on aripiprazole or when the dose of aripiprazole
was titrated upwards. All the patients carried a diagnosis of schizoaffective disorder
and an attempt was made to switch their antipsychotic medication to aripiprazole, as
it is believed to have a better side-effect profile.
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Case 1
Mrs CP is a 49-year-old African American woman who had
a long history of schizoaffective disorder. After multiple
medication trials she had been stabilized on citalopram
20 mg/day and quetiapine 100 mg at bedtime. However, the
patient was unhappy with her weight gain and wanted to
have her medication changed. She was started on
aripiprazole 15 mg/day po and quetiapine was decreased by
25 mg every 2 weeks. The patient complained of akathisia
(feeling restless in her legs) after being on aripiprazole
for 2 weeks. At that time aripiprazole was decreased to
10 mg/day. She reported decreased “restlessness” of her legs
the following week which decreased further with time and
no further change in aripiprazole dose. She was stable on
10 mg/day of aripiprazole and 20 mg/day of citalopram.
Case 2
Ms DC is a 32-year-old single white woman who worked
as a secretary and lived with her boyfriend. She has a
diagnosis of schizoaffective disorder with delusions of being
watched and followed, in association with symptoms of
mania and anxiety. Over the years the patient had been on
various antipsychotics including risperidone (minimal
response) and ziprasidone (developed palpitations). She had
been free of psychotic symptoms and stable on olanzapine
at 10 mg at bedtime; however, because a weight gain of about
18 kg had made her extremely unhappy, she started self-
tapering the olanzapine. Additionally, she had been
prescribed sodium valproate 1000 mg at bedtime, paroxetine
40 mg/day, topiramate 50 mg at bedtime, and lorazepam
1 mg as needed. As she stopped her olanzapine she was
started on aripiprazole 15 mg/day. Within a week she
complained of severe restlessness (unable to sit still at work)
and increased anxiety. She refused to continue with
aripiprazole. Subsequently, she became psychotic and was
stabilized on molindone 50 mg at bedtime.
Case 3
Ms DJ is a 39-year-old single white female, who has had
psychiatric problems since 14 years of age. She has a
diagnosis of schizoaffective disorder and has been
hospitalized multiple times and has had multiple medication
trials. Her psychotic symptoms consist of auditory
hallucinations and paranoia in addition to depression and
anxiety. She also exhibits self-injurious behavior. Over the
years she has been on different antipsychotics with moderate
improvement and also moderate side-effects (weight gain,
sedation). The patient was on olanzapine but this was tapered
off and aripiprazole 15 mg/day started due to persistence of
symptoms and weight gain. As her hallucinations continued,
aripiprazole was increased to 30 mg/day. However, the
patient became suicidal in response to auditory
hallucinations and needed to be hospitalized. She was started
on haloperidol, which was increased to 5 mg three times a
day. However, her auditory hallucinations continued and
aripiprazole was increased to 50 mg/day. At this point, the
patient developed severe akathisia – she was unable to sit
or stand still and felt she was going to jump out of her skin.
Haloperidal was decreased to 5 mg at bedtime, but the
akathisia continued. Propanolol was added at 20 mg twice
daily with minimal improvement. At this point aripiprazole
was decreased to 30 mg/day and the restlessness (akathisia)
decreased, and she was maintained at this dose. It should
be noted that at the time the patient developed akathisia she
was also on citalopram 60 mg/day, levothyroxine 50 µg/day,
hydroxyzine 100 mg at bedtime, buspirone 7.5 mg twice
daily, and triazolam 0.5 mg at bedtime, all of which were
unchanged during the course of events.
Case 4
Mr MW is a 29-year-old single white male, who became
extremely paranoid about 2 years ago and was unable to
trust his family members or leave his home. He was
hospitalized briefly and discharged on risperidone 3 mg/day.
During the patient’s outpatient treatment it was noted that
he was unable to sit still in groups and constantly paced up
and down. Although he did not complain he told his peers
that he felt he was jumping out of his skin. In view of these
side-effects his medications were switched to olanzapine,
titrated to 10 mg at bedtime, which controlled his symptoms.
Subsequently, the patient gained more than 23 kg (over one
year) and continued exhibiting negative symptoms, some
depression and some obsessive-compulsive symptoms. The
patient’s family was worried about his physical health and
it was decided to switch the patient to aripiprazole, which
was started at 15 mg/day, and olanzapine was decreased to
7.5 mg/day. In addition the patient was also on paroxetine
40 mg/day and buspirone 7.5 mg twice daily, which
remained unchanged. After a week the patient’s family noted
that he was more alert, and exhibiting fewer negative
symptoms; however, the patient complained of severe
restlessness and agitation. Aripiprazole was continued with
follow-up one week later. The patient returned, denying
anxiety but complaining of his inability to sit or stand still.
It was noted that he was constantly fidgeting a lot, which
had never been noted earlier. The patient also stated that heNeuropsychiatric Disease and Treatment 2006:2(2) 243
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could not tolerate this symptom, he refused to continue with
this medication, and stated that he wanted to return to
olanzapine. Aripiprazole was therefore discontinued.
Olanzapine was restarted at 7.5 mg at bedtime and the
akathisia resolved.
Discussion
The following factors may be related to the development of
akathisia in the cases described in this report.
Akathisia secondary to conventional antipsychotic agents
is frequently attributed to D2 receptor blockade in the
mesocortical areas (Marsden and Jenner 1980). It is likely
that this mechanism may also cause akathisia secondary to
treatment with aripiprazole.
The hepatic microsomal enzymes CYP3A4 and
CYP2D6 are primarily responsible for the metabolism of
aripiprazole. CYP2D6 is inhibited by fluoxetine and
paroxetine, which may in turn inhibit aripiprazole
breakdown and thus increase its blood levels. SSRIs may
also cause akathisia, perhaps a consequence of sero-
tonergically mediated inhibition of the dopaminergic system
(Lane 1998). All of the patients reported in this case series
were on a SSRI. Furthermore, the risk of akathisia secondary
to SSRI treatment may be heightened by the concomitant
use of an antipsychotic medication (Gerber and Lynd 1998).
Lastly, patients with affective symptoms have an increased
risk of developing EPS and akathisia. All patients included
in this report were diagnosed with schizoaffective disorder.
In summary it is noted that aripiprazole did cause
symptoms of akathisia in patients who had not experienced
their symptoms on their previous antipsychotic agents. These
symptoms appeared to be dose-related. It appears that
decreasing the dose in at least two cases caused a resolution
of their symptoms. There was no correlation between the
onset, severity, or resolution of akathisia with clinical
symptoms for the patients described in this report.
Three of these patients were started on aripiprazole at
15 mg/day and it has been our clinical experience that
starting aripiprazole at lower doses, either 5 or 10 mg/day,
minimizes the risk of akathisia and that starting at doses
greater than 30 mg/day increases the risk. We feel that
akathisia may be dose-related, particularly in cases in which
there is an additional SSRI. Further investigation into the
risk of akathisia secondary to aripiprazole treatment may
be beneficial.
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